Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Man lost 54 Kgs in 6 months with MGB procedure
Younger Indians have a 10 times higher rate of heart attack
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
To address the preventive & primary healthcare delivery gaps in India
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Subscribe To Our Newsletter & Stay Updated
